Evidence-based practices in geriatric mental health care: An overview of systematic reviews and meta-analyses

Psychiatric Clinics of North America

Volumn 26, Issue 4, 2003, Pages 971-990

  Bartels, Stephen J ^a,b   Dums, Aricca R ^b   Oxman, Thomas E ^a   Schneider, Lon S ^c   Areán, Patricia A ^d   Alexopoulos, George S ^e   Jeste, Dilip V ^f  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LONG ACTING DRUG; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

AGITATION; ALCOHOLISM; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GERIATRIC CARE; GERONTOPSYCHIATRY; HEADACHE; HEALTH CARE DELIVERY; HEALTH PROMOTION; HEART ARRHYTHMIA; HUMAN; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; META ANALYSIS; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PHYSICAL DISABILITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; WEIGHT REDUCTION;

EID: 0346733318     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(03)00072-8     Document Type: Review

References (98)

1. Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next two decades. Arch Gen Psychiatry 1999;56(9):848-53.
2. US Department of Health and Human Services. Mental health: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health; 1999.
3. Administration on Aging. Older adults and mental health: issues and opportunities. Rockville, MD: Department of Health and Human Services; 2001.
4. Banerjee S, Dickinson E. Evidence-based health care in old age psychiatry. Int J Psychiatry Med 1997;27(3):283-92.
5. Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999;14(3):231-9.
6. Bartels SJ. Quality, costs, and effectiveness of services for older adults with mental disorders: a selective overview of recent advances in geriatric mental health services research. Curr Opin Psychiatry 2002;15(4):411-6.
7. Oxman TE. Antidepressants and cognitive impairment in the elderly. J Clin Psychiatry 1996;57(Suppl 5):38-44.
8. Burke WJ, Folks DG, McNeilly DP. Effective use of anxiolytics in older adults. Clin Geriatr Med 1998;14(1):47-65.
9. The Cochrane Collaboration. Why the Cochrane collaboration? [internet]. 6/21/2002. Available at: http://www.cochrane.org/cochrane/archieco.htm. Accessed August 1, 2002.
10. Guyatt G, Rennie D. Users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago: AMA Press; 2002.
11. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence-based medicine: what it is and what it isn't. BMJ 1996;312(7023):71-2.
12. Robins LN, Regier DA. Psychiatric disorders in America: the epidemiologic Catchment Area Study. New York: The Free Press; 1991.
13. Alexopoulos GS, Katz IR, Reynolds CF, et al. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgraduate Medicine Special Report, October 2001; The McGraw-Hill Companies, Inc.,1-86.
14. Mulsant BH, Alexopoulos GS, Reynolds CF III, et al. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry 2001;16(6):585-92.
15. ASHP therapeutic position statement on the recognition and treatment of depression in older adults: American Society of Health System Pharmacists. Am J Health Syst Pharm 1998;55(23):2514-8.
16. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life. Consensus statement update. JAMA 1997;278(14):1186-90.
17. National Institutes of Health. NIH Consensus development conference statement: diagnosis and treatment of depression in late life. JAMA 1992;268(8):1018-24.
18. Gerson S, Belin TR, Kaufman A, et al. Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings. Harv Rev Psychiatry 1999;7(1):1-28.
19. Thorpe L, Whitney DK, Kutcher SP, et al. Clinical guidelines for the treatment of depressive disorders VI. Special populations. Can J Psychiatry 2001;46(Suppl 1):63S-76S.
20. Wilson K, Mottram P, Sivanranthan A, et al. Antidepressant versus placebo for depressed elderly (Cochrane review). Cochrane library. Oxford (UK): Update Software; 2002.
21. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;5819-36.
22. Mulrow CD, Williams JW, Trivedi M, et al. Treatment of depression - newer pharmacotherapies. Rockville, MD: Agency for Health Care Policy and Research; 1999. Evidence Report/Technology Assessment Number 7; AHCPR Publication No. 99-E014.
23. McCusker J, Cole M, Keller E, et al. Effectiveness of treatments of depression in older ambulatory patients. Arch Intern Med 1998;158(13):705-12.
24. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 1997;46(3):191-217.
25. Menting JE, Honig A, Verhey FR, et al. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side effects. Int Clin Psychopharmacol 1996;11(3):165-75.
26. Dunbar GC. Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology 1995;51(3):137-44.
27. Reynolds CF, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999;281(1):39-45.
28. Lenze EJ, Dew MA, Mazumdar S, et al. Combined pharmacotherapy and psychotherapy as maintenance treatment for late life depression: effects on social adjustment. Am J Psychiatry 2002;159(3):466-8.
29. Laidlaw K. An empirical review of cognitive therapy for late life depression: does research evidence suggest adaptations are necessary for cognitive therapy with older adults. Clinical Psychology Psychotherapy 2001;8(1):1-14.
30. Gatz M, Fiske A, Fox LS, et al. Empirically validated psychological treatments for older adults. J Ment Health Aging 1998;4(1):9-46.
31. Pinquart M, Sorensen S. How effective are psychotherapeutic and other psychosocial interventions with older adults? A meta-analysis. J Ment Health Aging 2001;7(2):207-43.
32. Cuijpers P. Psychological outreach programmes for the depressed elderly: a meta-analysis of effects and dropouts. Int J Geriatr Psychiatry 1998;13(1):41-8.
33. Engels GI, Verney M. Efficacy of nonmedical treatments of depression in elders: a quantitative analysis. Journal of Clinical Geropsychology 1997;3(1):17-35.
34. Koder DA, Brodaty H, Anstey KJ. Cognitive therapy for depression in the elderly. Int J Geriatr Psychiatry 1996;11(2):97-107.
35. Scogin F, McElreath L. Efficacy of psychosocial treatments for geriatric depression: a quantitative review. J Consult Clin Psychol 1994;62(1):69-74.
36. Lima MS, Moncrieff J. Drugs versus placebo for dysthymia (Cochrane review). Cochrane library. Oxford (UK): Update Software; 2002.
37. Oxman TE, Sengupta AS. Treatment of Minor Depression. Am J Geriatr Psychiatry 2002;10(3):256-64.
38. Pearson JL, Brown GK. Suicide prevention in late life: directions for science and practice. Clin Psychol Rev 2000;20(6):685-705.
39. Bartels SJ, Dums AR, Oxman TE, et al. Evidence-based practices in geriatric mental health care. Psychiatr Serv 2002;53(11):1419-31.
40. Qizilbash N, Schneider L, Brodaty H, et al. Evidence-based dementia practice. Oxford (UK): Blackwell Publishers; 2002.
41. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278(16):1363-71.
42. Patterson CJ, Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J 1999;160:S1-15.
43. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 2001;28(Suppl 1):S96-S107.
44. Kindermann SS, Dolder CR, Bailey A, et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging 2002;19(4):257-76.
45. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1154-66.
46. Kasl-Godley J, Gatz M. Psychosocial interventions for individuals with dementia: an integration of theory, therapy, and a clinical understanding of dementia. Clin Psychol Rev 2000;20(6):755-82.
47. Emre M, Hanaoasi HA. Evidence-based pharmacological treatment of dementia. Eur J Neurol 2000;7(3):247-53.
48. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154(Suppl 5):1-39.
49. Kirchner V, Kelley CA, Harvey RJ. Thioridazine for dementia (Cochrane review). Cochrane library. Oxford (UK): Update Software; 2002.
50. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia (Cochrane review). Cochrane library. Oxford (UK): Update Software; 2002.
51. Lanctot KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998;59(10):550-61.
52. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38(5):553-63.
53. Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia (Cochrane review). Cochrane library. Oxford (UK): Update Software; 2002.
54. Alexopoulos GS, Silver JM, Kahn DA, et al. The expert consensus guideline series: agitation in older persons with dementia. A Postgraduate Medicine Special Report, April; 1998;1-88.
55. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis. JAMA 2003;289(2):210-6.
56. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999;341(22):1670-9.
57. Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 2002;52(3):243-52.
58. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia. Am J Geriatr Psychiatry 2001;9(4):361-81.
59. Allen-Burge R, Stevens AB, Burgio LD. Effective behavioral interventions for decreasing dementia-related challenging behavior in nursing homes. Int J Geriatr Psychiatry 1996;14(3):213-28.
60. Sorensen S, Pinquart M, Duberstein P. How effective are interventions with caregivers? An updated meta-analysis. Gerontologist 2002;423:356-72.
61. Anand R, Hartman R, Sohn H, et al. Impact of study design and patient population on outcomes from cholinesterase inhibitor trials. Am J Geriatr Psychiatry 2003;11(2):160-8.
62. Elie M, Cole MG, Primeau FJ, et al. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med 1998;13(3):204-12.
63. Cole MG, Primeau FJ. Prognosis of delirium in elderly hospital patients. Can Med Assoc J 1993;149(1):41-6.
64. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999;156(Suppl 5):1-20.
65. Council on Scientific Affairs. American Medical Association. Alcoholism in the elderly. JAMA 1996;275(10):797-801.
66. Center for Substance Abuse Treatment. Treatment improvement protocol (TIP) #26. Substance Abuse Among Older Adults. Rockville, MD: US Department of Health and Human Services. Public health Service, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 1998.
67. Schonfeld L, Dupree LW. Treatment approaches for older problem drinkers. Int J Addict 1995;30:1819-42.
68. Fingerhood M. Substance abuse in older people. J Am Geriatr Soc 2000;48(8):985-95.
69. Blow FC, Barry KL. Older patients with at-risk and problem drinking patterns: new developments in brief interventions. J Geriatr Psychiatry Neurol 2000;13(3):115-23.
70. Cohen CI, Cohen GD, Blank K, et al. Schizophrenia and older adults. An overview: directions for research and policy. Am J Geriatr Psychiatry 2000;8(1):19-28.
71. Soares JC, Gershon S. Therapeutic targets in late-life psychoses: review of concepts and critical issues. Schizophr Res 1997;27:227-39
72. Lake JT, Rahman AH, Grossberg GT. Diagnosis and treatment of psychotic symptoms in elderly patients. Drugs Aging 1997;11(3):170-7.
73. Sable JA, Jeste DV. Antipsychotic treatment for late-life schizophrenia. Curr Psychiatry Rep 2002;4(4):299-306.
74. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999;60(Suppl 8):29-41.
75. Finkel SI. Antipsychotics: old and new. Clin Geriatr Med 1998;14(1):87-100.
76. Chan YC, Pariser SF, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy 1999;19(7):811-22.
77. Kumar V. Use of atypical antipsychotic agents in geriatric patients: a review. International Journal of Geriatric Psychopharmacology 1997;1:15-23.
78. Sweet RA, Pollock BG. New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging 1998;12(2):115-27.
79. Bullock R, Saharan A. Atypical antipsychotics: experience and use in the elderly. Int J Clin Pract 2002;56(7):515-25.
80. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35(1):51-68.
81. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321(7273):1371-6.
82. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157(7):1150-5.
83. Patterson TL, McKibbin C, Taylor M, et al. Functional adaptation skills training (FAST): a pilot psychosocial intervention study in middle-aged and older patients with chronic psychotic disorders. Am J Geriatr Psychiatry 2003;11(1):17-23.
84. Granholm E, McQuaid JR, McClure FS, et al. A randomized controlled pilot study of cognitive behavioral social skills training for older patients with schizophrenia. Schizophr Res 2002;53:167-9.
85. Bartels SJ, Forester B, Mueser KT. et al. Enhanced skills training and health care management for older persons with severe mental illness. Community Ment Health J, in press.
86. Stanley MA, Beck JG. Anxiety disorders. Clin Psychol Rev 2000;20(6):731-54.
87. Katz IR, Reynolds CF, Alexopoulos GS, et al. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002;50(1):18-25.
88. Stanley MA, Novy DM. Cognitive-behavior therapy for generalized anxiety in late life: an evaluative overview. J Anxiety Disord 2000;14(2):191-207.
89. Draper B. The effectiveness of old age psychiatry services. Int J Geriatr Psychiatry 2000;15(8):687-703.
90. Bartels SJ, Moak GS, Dums AR. Mental health services in nursing homes: models of mental health services in nursing homes: a review of the literature. Psychiatr Serv 2002;53(11):1390-6.
91. Flather MD, Farkouh ME, Pogue JM, et al. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials 1997;18(6):568-79.
92. American Psychiatric Association. American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: compendium 2002. 2nd edition. Washington (DC): American Psychiatric Publishing; 2002.
93. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999;281(20):1900-5.
94. Grilli R, Margrini N, Penna A, et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000;355(9198):103-6.
95. Lo B, Wolf LE, Berkeley A. Conflict-of-interest policies for investigators in clinical trials. N Engl J Med 2000;343(22):1616-20.
96. Bodenheimer T. Uneasy alliance - clinical investigators and the pharmaceutical industry. N Engl J Med 2000;342(20):1539-44.
97. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283(3):373-80.
98. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287(5):612-7.